NL301352I2 - epcoritamab - Google Patents

epcoritamab

Info

Publication number
NL301352I2
NL301352I2 NL301352C NL301352C NL301352I2 NL 301352 I2 NL301352 I2 NL 301352I2 NL 301352 C NL301352 C NL 301352C NL 301352 C NL301352 C NL 301352C NL 301352 I2 NL301352 I2 NL 301352I2
Authority
NL
Netherlands
Prior art keywords
epcoritamab
Prior art date
Application number
NL301352C
Other languages
Dutch (nl)
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/050340 external-priority patent/WO2014108483A1/en
Application filed by Genmab As filed Critical Genmab As
Publication of NL301352I2 publication Critical patent/NL301352I2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NL301352C 2014-01-09 2025-11-25 epcoritamab NL301352I2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2014/050340 WO2014108483A1 (en) 2013-01-10 2014-01-09 Inert format
DKPA201400009 2014-01-09
PCT/EP2014/064326 WO2015001085A1 (en) 2013-07-05 2014-07-04 Humanized or chimeric cd3 antibodies
EP15700081.1A EP3091998B1 (en) 2014-01-09 2015-01-08 Humanized or chimeric cd3 antibodies
PCT/EP2015/050276 WO2015104346A1 (en) 2014-01-09 2015-01-08 Humanized or chimeric cd3 antibodies

Publications (1)

Publication Number Publication Date
NL301352I2 true NL301352I2 (en) 2025-12-16

Family

ID=52143134

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301352C NL301352I2 (en) 2014-01-09 2025-11-25 epcoritamab

Country Status (32)

Country Link
US (5) US10465006B2 (en)
EP (5) EP3693385A1 (en)
JP (7) JP6546162B2 (en)
KR (4) KR102363220B1 (en)
CN (5) CN113248615B (en)
AU (4) AU2014286116A1 (en)
BR (1) BR122023002590B1 (en)
CA (1) CA2915575A1 (en)
CY (1) CY1122840T1 (en)
DK (2) DK3016681T5 (en)
EA (1) EA201690167A1 (en)
ES (3) ES2776706T3 (en)
FI (2) FI4249515T3 (en)
FR (1) FR25C1054I1 (en)
HR (2) HRP20200382T1 (en)
HU (3) HUE048722T2 (en)
IL (4) IL290613B2 (en)
LT (3) LT3016681T (en)
ME (1) ME03675B (en)
MX (2) MX373245B (en)
NL (1) NL301352I2 (en)
NO (1) NO2025057I1 (en)
NZ (1) NZ715896A (en)
PL (2) PL3016681T3 (en)
PT (2) PT3016681T (en)
RS (2) RS60131B1 (en)
SG (2) SG10201800982QA (en)
SI (2) SI3016681T1 (en)
SM (2) SMT202000287T1 (en)
UA (1) UA119646C2 (en)
WO (2) WO2015001085A1 (en)
ZA (1) ZA201800385B (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI638833B (en) 2010-11-30 2018-10-21 中外製藥股份有限公司 Cell damage induction treatment
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
TWI682941B (en) 2013-02-01 2020-01-21 美商再生元醫藥公司 Antibodies comprising chimeric constant domains
KR102363220B1 (en) * 2013-07-05 2022-02-15 젠맵 에이/에스 Humanized or chimeric cd3 antibodies
JP6693872B2 (en) 2013-07-25 2020-05-13 シトムクス セラピューティクス，インコーポレイティド Multispecific antibodies, multispecific activatable antibodies, and methods of use thereof
TWI754319B (en) 2014-03-19 2022-02-01 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
KR102568808B1 (en) * 2014-04-07 2023-08-18 추가이 세이야쿠 가부시키가이샤 Immunoactivating antigen-binding molecule
SG11201609370QA (en) 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
ES2809455T3 (en) 2014-11-17 2021-03-04 Regeneron Pharma Methods for tumor treatment using CD3xCD20 bispecific antibody
BR112017010513A2 (en) 2014-11-20 2018-04-03 F. Hoffmann-La Roche Ag Common light chains and methods of use
EP3221356B1 (en) 2014-11-20 2020-09-02 F.Hoffmann-La Roche Ag T cell activating bispecific antigen binding molecules against folr1 and cd3
WO2016110576A1 (en) 2015-01-08 2016-07-14 Genmab A/S Bispecific antibodies against cd3 and cd20
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
IL310723A (en) * 2015-04-13 2024-04-01 Pfizer Therapeutic antibodies and their uses
PL3322727T3 (en) * 2015-07-15 2026-05-11 Genmab A/S Humanized or chimeric cd3 antibodies
KR102777500B1 (en) 2015-09-23 2025-03-11 리제너론 파아마슈티컬스, 인크. Optimized anti-CD3 bispecific antibodies and uses thereof
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION
WO2017086367A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
CN105296421B (en) * 2015-11-24 2019-01-29 高岱清 The T cell and preparation method of a kind of activation of bispecific antibody and application
AU2016368469B2 (en) 2015-12-09 2023-11-02 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
CN116769054A (en) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 Bispecific signaling agents and uses thereof
LT3433280T (en) * 2016-03-22 2023-07-10 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
MA43724B1 (en) * 2016-03-22 2023-06-28 Hoffmann La Roche BI-SPECIFIC PROTEASE-ACTIVATED T-CELL MOLECULES
CN110603266A (en) 2016-06-02 2019-12-20 豪夫迈·罗氏有限公司 Type II anti-CD 20 and anti-CD 20/CD3 bispecific antibodies for the treatment of cancer
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
JP7461741B2 (en) 2016-06-20 2024-04-04 カイマブ・リミテッド Anti-PD-L1 and IL-2 Cytokines
UA128304C2 (en) * 2016-07-14 2024-06-05 Ґенмаб А/С MULTISPECIFIC ANTIBODY TO CD40 AND CD137
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CN110573172A (en) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 Targeted engineered interferon and uses thereof
PT3592769T (en) 2017-03-09 2024-07-31 Genmab As Antibodies against pd-l1
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
AU2018266711B2 (en) * 2017-05-08 2025-02-06 Adimab, Llc Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
TWI728250B (en) 2017-06-21 2021-05-21 美商基利科學股份有限公司 Multispecific antibodies that target hiv gp120 and cd3
IL272159B2 (en) 2017-08-04 2026-03-01 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
US20190100587A1 (en) * 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
US11472889B2 (en) 2017-10-14 2022-10-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
KR101973060B1 (en) * 2017-10-20 2019-04-26 주식회사 녹십자 Antibody against cd3 and pharmaceutical composition for treating cancer comprising the same
CN107860925B (en) * 2017-11-03 2019-07-12 合肥瀚科迈博生物技术有限公司 For detecting the ELISA detection kit of HuA21 antibody in serum
CN109971725B (en) 2017-12-28 2024-02-02 上海细胞治疗研究院 Antibody-modified chimeric antigen receptor-modified T cells and uses thereof
SG11202007572VA (en) * 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
CR20250347A (en) 2018-03-12 2025-09-23 Genmab As ANTIBODIES BONDING TO 5T4 (Divisional 2020-0463)
CN120399075A (en) * 2018-03-14 2025-08-01 诺维莫尼公司 Anti-CD3ε antibodies and their use methods
DK3797121T3 (en) * 2018-05-23 2024-07-08 Pfizer Antibodies specific for CD3 and uses thereof
CN112912397B (en) * 2018-05-24 2025-03-14 詹森生物科技公司 Anti-CD3 antibodies and uses thereof
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
PT3844189T (en) 2018-08-31 2025-01-29 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
EP3864045A2 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CA3115082A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
CN113518647A (en) 2018-10-11 2021-10-19 印希比股份有限公司 5T4 single domain antibodies and therapeutic compositions thereof
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP7621948B2 (en) * 2018-12-04 2025-01-27 ノバルティス アーゲー Binding molecules to CD3 and uses thereof
UY38701A (en) 2019-05-21 2020-12-31 Novartis Ag MOLECULES OF BINDING TO CD19, CONJUGATES, COMPOSITIONS THAT INCLUDE THEM AND USES OF THE SAME
CN118994397A (en) 2019-05-21 2024-11-22 诺华股份有限公司 Trispecific binding molecules directed against BCMA and uses thereof
WO2021048423A1 (en) 2019-09-12 2021-03-18 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
TWI841790B (en) * 2019-09-30 2024-05-11 大陸商和鉑醫藥（上海）有限責任公司 Antibodies targeting CD3, bispecific antibodies and their uses
CN121197633A (en) 2019-12-13 2025-12-26 比特比德科有限责任公司 Ingestible device for delivering therapeutic agents to the gastrointestinal tract
MX2022007486A (en) 2019-12-23 2022-06-29 Denali Therapeutics Inc PROGRANULIN VARIANTS.
US12545731B2 (en) 2020-01-06 2026-02-10 Cytomx Therapeutics, Inc. Single-and multi-chain polypeptides that bind specifically to CD3 epsilon
IL294879A (en) 2020-01-29 2022-09-01 Inhibrx Inc Cd28 single domain antibodies and multivalent and multispecific constructs thereof
WO2021167952A2 (en) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
EP4121456A1 (en) 2020-03-18 2023-01-25 Genmab A/S Antibodies binding to b7h4
CN113563473A (en) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 Tetravalent bispecific antibody, preparation method and application thereof
BR112022022730A2 (en) * 2020-05-08 2023-02-14 Genmab As METHOD FOR TREATMENT OF B-CELL NON-HODGKIN LYMPHOMA IN A HUMAN INDIVIDUAL
CA3184189A1 (en) 2020-05-27 2021-12-02 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
AU2021333577B2 (en) 2020-08-25 2025-09-11 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting HIV and methods of use
JP2023539525A (en) 2020-09-02 2023-09-14 ジェンマブ エー／エス antibody therapy
EP4210744A1 (en) 2020-09-10 2023-07-19 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
US20240034812A1 (en) 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CA3192256A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
US20230312758A1 (en) 2020-09-10 2023-10-05 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
EP4210746A1 (en) 2020-09-10 2023-07-19 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
BR112023004216A2 (en) 2020-09-10 2023-04-11 Genmab As METHOD TO TREAT FOLLICULAR LYMPHOMA IN A HUMAN SUBJECT
KR20230080437A (en) 2020-10-02 2023-06-07 젠맵 에이/에스 Antibodies capable of binding ROR2 and bispecific antibodies binding ROR2 and CD3
KR102671734B1 (en) * 2021-04-13 2024-06-04 건국대학교 글로컬산학협력단 NOVEL CANINE CD3ε SPECIFIC ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF
AU2021443863A1 (en) 2021-04-30 2023-10-26 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
WO2022228705A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
AR125815A1 (en) 2021-05-07 2023-08-16 Genmab As PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES THAT BIND B7H4 AND CD3
CN115558023A (en) * 2021-07-02 2023-01-03 安源医药科技（上海）有限公司 anti-CD 3 antibodies and uses thereof
AR127298A1 (en) 2021-10-08 2024-01-10 Genmab As ANTIBODIES THAT BIND CD30 AND CD3
EP4469083A1 (en) 2022-01-28 2024-12-04 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
JP2025503176A (en) 2022-01-28 2025-01-30 ジェンマブ エー／エス Bispecific antibodies against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma - Patents.com
WO2023180353A1 (en) 2022-03-23 2023-09-28 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
US20250304689A1 (en) 2022-04-13 2025-10-02 Genmab A/S Bispecific antibodies against cd3 and cd20
CA3255366A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
CN119212716A (en) * 2022-05-09 2024-12-27 杭州微诺迈博生物科技有限公司 Therapeutic agents comprising multispecific antibodies and their use in tumor treatment
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
EP4612179A1 (en) 2022-11-02 2025-09-10 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating richter's syndrome
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
CN121240884A (en) 2023-04-05 2025-12-30 根马布股份公司 Pharmaceutical compositions containing antibodies that bind to CD30 and CD3
CN121311504A (en) 2023-04-13 2026-01-09 金麦安博股份有限公司 Treatment of lymphoma with bispecific antibodies targeting CD3 and CD20
EP4695308A1 (en) * 2023-09-14 2026-02-18 Invitrogen BioServices India Private Limited Engineered antibodies and uses thereof
EP4590714A1 (en) 2023-09-21 2025-07-30 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2025061994A1 (en) 2023-09-21 2025-03-27 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2025116732A1 (en) * 2023-12-01 2025-06-05 Rijksuniversiteit Groningen Methods and kits for detecting proliferating cells
WO2025199352A2 (en) 2024-03-20 2025-09-25 Juno Therapeutics, Inc. Antibodies specific for solute carrier family 34 member 2 (slc34a2)
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE255131T1 (en) 1991-06-14 2003-12-15 Genentech Inc HUMANIZED HEREGULIN ANTIBODIES
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (en) 1995-11-03 1997-06-26 김광호 Precharge Circuit of Semiconductor Memory Device
DK0979281T3 (en) 1997-05-02 2005-11-21 Genentech Inc Process for the preparation of multispecific antibodies with heteromultimers and common components
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
DE10043437A1 (en) 2000-09-04 2002-03-28 Horst Lindhofer Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
KR20110017020A (en) * 2002-10-17 2011-02-18 젠맵 에이/에스 Human monoclonal antibodies against CD20
PT1737891E (en) 2004-04-13 2013-04-16 Hoffmann La Roche Anti-p-selectin antibodies
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
EP2388271A3 (en) * 2005-02-03 2012-08-01 Antitope Limited Human Antibodies and Proteins
EP2395026B1 (en) 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Method for improving antibody
CN101198698B (en) 2005-03-31 2014-03-19 中外制药株式会社 Process for production of polypeptide by regulation of assembly
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5364870B2 (en) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulins and uses thereof
JP5686953B2 (en) * 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー Compositions comprising cross-species-specific antibodies and uses of the compositions
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CN103073639A (en) 2006-03-17 2013-05-01 比奥根艾迪克Ma公司 Stabilized polypeptide compositions
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
AT503902B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
SG10201808730VA (en) 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
US20100183615A1 (en) * 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
CA2691434C (en) 2007-06-21 2020-07-21 Macrogenics, Inc. Covalent diabodies and uses thereof
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
DE102008039957A1 (en) 2008-08-27 2010-03-04 Continental Automotive Gmbh Method for determining an accident severity criterion by means of an acceleration signal and a structure-borne sound signal
JP5397668B2 (en) 2008-09-02 2014-01-22 ソニー株式会社 Storage element and storage device
FR2935974B1 (en) 2008-09-15 2010-10-08 Centre Nat Rech Scient DERIVATIVES OF METALLOPORPHYRINS, NANOPARTICLES COMPRISING THE SAME
CA2738568C (en) * 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
JP2012505654A (en) * 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド Methods for humanizing and affinity maturating antibodies
ES2733067T3 (en) 2008-12-19 2019-11-27 Macrogenics Inc Covalent diabodies and uses thereof
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
SI2506871T1 (en) 2009-11-30 2016-12-30 Janssen Biotech, Inc. ANTIBODY Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
US8786135B2 (en) 2010-03-25 2014-07-22 Mitsubishi Electric Research Laboratories, Inc. Wireless energy transfer with anisotropic metamaterials
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
TWI653333B (en) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 Cross-species specific PSMAxCD3 bispecific single chain antibody
JP6040148B2 (en) 2010-04-20 2016-12-07 ゲンマブ エー／エス Heterodimeric antibody Fc-containing protein and production method thereof
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
EP2593475B1 (en) * 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
AR082693A1 (en) * 2010-08-17 2012-12-26 Roche Glycart Ag COMBINATION THERAPY OF AN ANTI-CD20 AFUCOSILATED ANTIBODY WITH AN ANTI-VEGF ANTIBODY
RU2013110875A (en) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг SPECIFIC ANTIBODIES CONTAINING DISSULPHIDE-STABILIZED Fv Fragment
RU2013110876A (en) 2010-08-24 2014-09-27 Рош Гликарт Аг ACTIVATED SPECIFIC ANTIBODIES
PL2635607T3 (en) 2010-11-05 2020-05-18 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
TWI638833B (en) * 2010-11-30 2018-10-21 中外製藥股份有限公司 Cell damage induction treatment
TW201238976A (en) * 2011-02-23 2012-10-01 Hoffmann La Roche Antibodies against human IL33R and uses thereof
AU2012245116A1 (en) * 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
US9587021B2 (en) 2011-05-21 2017-03-07 Macrogenics, Inc. CD3-binding molecules capable of binding to human and non-human CD3
CN102250246A (en) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 Bispecific antibody to VEGF/PDGFR beta and application thereof
DK2771364T3 (en) 2011-10-27 2019-08-19 Genmab As PREPARATION OF HETERODIMERED PROTEINS
SG11201404321YA (en) * 2012-01-27 2014-08-28 Neotope Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
KR102363220B1 (en) 2013-07-05 2022-02-15 젠맵 에이/에스 Humanized or chimeric cd3 antibodies
CN105531374A (en) * 2013-07-12 2016-04-27 酵活有限公司 Bispecific CD3 and CD19 antigen-binding constructs
MX379030B (en) * 2013-12-17 2025-03-10 Genentech Inc Anti-cd3 antibodies and methods of use
WO2016110576A1 (en) 2015-01-08 2016-07-14 Genmab A/S Bispecific antibodies against cd3 and cd20
PL3322727T3 (en) 2015-07-15 2026-05-11 Genmab A/S Humanized or chimeric cd3 antibodies
CH713600A2 (en) 2017-03-21 2018-09-28 Digi Sens Ag Apparatus and method for measuring a load.
US11472880B2 (en) * 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
EP4210746A1 (en) * 2020-09-10 2023-07-19 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
US20240034812A1 (en) * 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
BR112023004216A2 (en) * 2020-09-10 2023-04-11 Genmab As METHOD TO TREAT FOLLICULAR LYMPHOMA IN A HUMAN SUBJECT
EP4210744A1 (en) * 2020-09-10 2023-07-19 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma

Also Published As

Publication number Publication date
LTPA2025538I1 (en) 2025-12-29
EP3016681A1 (en) 2016-05-11
SI3016681T1 (en) 2020-04-30
AU2025256200A1 (en) 2025-11-13
JP2022101539A (en) 2022-07-06
JP7104000B2 (en) 2022-07-20
IL276530B (en) 2022-03-01
DK3016681T5 (en) 2020-05-04
AU2022203851A1 (en) 2022-06-23
CN105722529A (en) 2016-06-29
ME03675B (en) 2020-10-20
JP7757247B2 (en) 2025-10-21
US10465006B2 (en) 2019-11-05
PT3016681T (en) 2020-03-26
JP2020005635A (en) 2020-01-16
IL290613B1 (en) 2024-07-01
DK4249515T3 (en) 2025-09-15
MX2015017487A (en) 2016-03-21
WO2015104346A1 (en) 2015-07-16
KR102531517B1 (en) 2023-05-12
EP4249515A2 (en) 2023-09-27
US20200123255A1 (en) 2020-04-23
ES3038421T3 (en) 2025-10-13
SG11201510739TA (en) 2016-01-28
BR122023002590B1 (en) 2023-12-05
UA119646C2 (en) 2019-07-25
NZ715896A (en) 2022-02-25
PT4249515T (en) 2025-09-08
JP6546162B2 (en) 2019-07-17
LT3016681T (en) 2020-03-25
JP2024026114A (en) 2024-02-28
JP7389833B2 (en) 2023-11-30
IL311371B1 (en) 2024-05-01
JP7208129B2 (en) 2023-01-18
CA2915575A1 (en) 2015-01-08
JP2017505121A (en) 2017-02-16
IL276530A (en) 2020-09-30
HK1231369A1 (en) 2017-12-22
HRP20200382T1 (en) 2020-06-12
HUS2500051I1 (en) 2025-12-28
JP2022163009A (en) 2022-10-25
EP4249515A3 (en) 2023-11-15
EA201690167A1 (en) 2016-06-30
CN113248615B (en) 2025-07-04
NO2025057I1 (en) 2025-12-11
AU2020202792B9 (en) 2022-07-07
SI4249515T1 (en) 2025-11-28
AU2022203851B2 (en) 2025-07-24
AU2020202792A1 (en) 2020-05-21
HUE072527T2 (en) 2025-11-28
KR20160027177A (en) 2016-03-09
PL4249515T3 (en) 2025-12-22
SMT202000287T1 (en) 2020-07-08
CN118063621A (en) 2024-05-24
BR112015032986A2 (en) 2017-08-22
CY1122840T1 (en) 2021-05-05
US20200199229A1 (en) 2020-06-25
KR102363220B1 (en) 2022-02-15
HUE048722T2 (en) 2020-08-28
SMT202500322T1 (en) 2025-11-10
MX2020004503A (en) 2020-08-13
JP2020048564A (en) 2020-04-02
KR102813816B1 (en) 2025-05-29
KR20230073341A (en) 2023-05-25
CN106255507B (en) 2025-05-02
AU2020202792B2 (en) 2022-06-23
CN105722529B (en) 2021-06-08
JP7851903B2 (en) 2026-04-27
LT4249515T (en) 2025-08-25
RS67220B1 (en) 2025-10-31
EP4631978A2 (en) 2025-10-15
CN113248615A (en) 2021-08-13
IL290613A (en) 2022-04-01
WO2015001085A1 (en) 2015-01-08
JP2016529882A (en) 2016-09-29
EP3091998B1 (en) 2025-08-20
IL311371A (en) 2024-04-01
HRP20251127T1 (en) 2025-11-21
IL290613B2 (en) 2024-11-01
AU2014286116A1 (en) 2016-02-04
EP3091998A1 (en) 2016-11-16
JP6619342B2 (en) 2019-12-11
CN106255507A (en) 2016-12-21
US20160333095A1 (en) 2016-11-17
EP3693385A1 (en) 2020-08-12
FI4249515T3 (en) 2025-09-02
US10407501B2 (en) 2019-09-10
RS60131B1 (en) 2020-05-29
CN120365424A (en) 2025-07-25
US11613575B2 (en) 2023-03-28
DK3016681T3 (en) 2020-03-09
FR25C1054I1 (en) 2026-01-16
ES3052034T3 (en) 2025-12-30
EP4631978A3 (en) 2025-12-24
ES2776706T3 (en) 2020-07-31
SG10201800982QA (en) 2018-03-28
US20160168247A1 (en) 2016-06-16
IL243127B (en) 2020-08-31
FIC20250036I1 (en) 2025-12-09
US20230374131A1 (en) 2023-11-23
MX373245B (en) 2020-05-11
EP3016681B1 (en) 2019-12-18
IL311371B2 (en) 2024-09-01
ZA201800385B (en) 2019-09-25
EP4249515B1 (en) 2025-06-18
KR20250078622A (en) 2025-06-02
KR20220025210A (en) 2022-03-03
PL3016681T3 (en) 2020-06-15

Similar Documents

Publication Publication Date Title
NO2025057I1 (en) epcoritamab
DK3183051T3 (en) LIQUID-TO-LUFTMEMBRANENERGIVEKSLERE
DK3134402T3 (en) 4-amino-imidazoquinoline
DK3211743T3 (en) E-to-network omskiftningsfremgangsmåde
DK3006072T3 (en) Karadgang
DK3222714T3 (en) PHYTASEMUTANTS
DK3119396T3 (en) MUSCARINRECEPTORAGONISTER
EP3230438C0 (en) N-GLYCOLISATION
EP4011484C0 (en) THERMOVIBRIO-AMMONIFICANS-CARBOANHYDRASE
DK4242916T3 (en) AMBULATOR
DK3183340T3 (en) TERMOLABILE EXONUCLEASER
DE112015001664A5 (en) Betätigungsaktuator
DK3154703T3 (en) FULLKAPPE-SNEKKECENTRIFUGE
DE112015005041A5 (en) GARGERÄTEVORRICHTUNG
DK3110439T3 (en) PCSK9-VACCINES
DE102014000623A8 (en) Halbhohlnietelement
DK3009858T3 (en) SKYRADAR
DE202014005655U8 (en) llluminationsvorrichtung
DE112015001633A5 (en) Betätigungsaktuator
DK3447493T3 (en) PROTEIN-ORATED ORTHOLOGISTS
ES1133830Y (en) COLUMBARY
DE112015005055A5 (en) Gargerätevorrichtung
DK3091875T3 (en) VIPBAR TABURET
ES1114205Y (en) HELIOSTATE
DK3191825T3 (en) CREATININBIOSENSOR